It was the first LBP using Bacteroides fragilis to receive FDA clearance for clinical trials in the U.S
It serves as both a therapeutic and preventive agent, and is the only LBP candidate in clinical development globally that can be used for the prevention of CID.
Repair mechanical barrier damage and enhance immune barrier.
(sk10)The world's first LBP to enter the clinical development usingBacteroides fragilis
IBS has urgent clinical needs and a large market capacity
SK08 is the only clinical-stage LBP candidate targeting pediatric rotavirus diarrhea globally
The first LBP to obtain registrational clinical trial approvals from both the NMPA and the U.S. FDA
SK08 is currently the only late-stage clinical biological drug candidate in the global IBS-D field
Urgent clinical needs and a large market capacity
As a benchmark in China’s second-generation LBP field
(sk08)Among LBPs for UC treatment in the clinical stage globally, SK08 is the only pipeline in China currently under clinical development.
SK08 has the potential to treat UC through multiple mechanisms, including repairing intestinal barrier protection and promoting mucosal healing, promoting intestinal immune tolerance and inhibiting inflammation, and regulating intestinal flora.
(sk08)there were two clinical-stage LBP products in China being developed for use in combination with PD-1 therapies for the treatment of solid tumor and SK08 is one of them.
Non-clinical study has shown that SK08 combined with PD-1 inhibitorcan enhance tumor reponses to immunotherapy and improve anti-tumor efficacy
(sk08)It was the first LBP using Bacteroides fragilis to receive FDA clearance for clinical trials in the U.S
It serves as both a therapeutic and preventive agent, and is the only LBP candidate in clinical development globally that can be used for the prevention of CID.
Repair mechanical barrier damage and enhance immune barrier.
(sk10)The world's first LBP to enter the clinical development usingBacteroides fragilis
IBS has urgent clinical needs and a large market capacity
SK08 is the only clinical-stage LBP candidate targeting pediatric rotavirus diarrhea globally
The first LBP to obtain registrational clinical trial approvals from both the NMPA and the U.S. FDA
SK08 is currently the only late-stage clinical biological drug candidate in the global IBS-D field
Urgent clinical needs and a large market capacity
As a benchmark in China’s second-generation LBP field
(sk08)Among LBPs for UC treatment in the clinical stage globally, SK08 is the only pipeline in China currently under clinical development.
SK08 has the potential to treat UC through multiple mechanisms, including repairing intestinal barrier protection and promoting mucosal healing, promoting intestinal immune tolerance and inhibiting inflammation, and regulating intestinal flora.
(sk08)there were two clinical-stage LBP products in China being developed for use in combination with PD-1 therapies for the treatment of solid tumor and SK08 is one of them.
Non-clinical study has shown that SK08 combined with PD-1 inhibitorcan enhance tumor reponses to immunotherapy and improve anti-tumor efficacy
(sk08)It was the first LBP using Bacteroides fragilis to receive FDA clearance for clinical trials in the U.S
It serves as both a therapeutic and preventive agent, and is the only LBP candidate in clinical development globally that can be used for the prevention of CID.
Repair mechanical barrier damage and enhance immune barrier.
(sk10)